Efficacy News and Research

RSS

Honeybees can be trained to identify SARS-CoV-2 infected samples, say scientists

In a recent study published on the bioRxiv* pre-print server, researchers from the Netherlands successfully trained honeybees (Apis mellifera) to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected minks (Neovison vison) using Pavlovian conditioning protocols.

21 Oct 2021

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

21 Oct 2021

Comparative effectiveness of ChAdOx1 and BNT162b2 COVID-19 vaccines

In a recent study, researchers compared the efficacy of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines against infection SARS-CoV-2.

21 Oct 2021

Comparison of social distancing policies in Denmark and Sweden to combat COVID-19

The current study included the national response of Denmark and Sweden to the COVID-19 pandemic.

21 Oct 2021

U.S. life expectancy may drop for the second year, minorities most affected

Scientists estimate the effect of the pandemic on life expectancy at birth, at 65 years overall, as well as for individual populations.

21 Oct 2021

Researchers identify a common gene variant that drives the efficiency and outcome of dialysis

Every day, the human kidneys clean about 1,500 liters of blood by producing approximately 1–2 liters of urine. Thereby, the body gets rid of excess water and toxic waste products of the metabolism or also drugs and maintains the balance of water and minerals in the tissues.

21 Oct 2021

CAR-T cell treatment's efficacy in hematological malignancies predicted by epigenetics

One in five cancers affects blood cells and lymph nodes, causing leukemias and lymphomas, respectively. Although their treatment with drugs has led to a great advance in their cure, there are cases where there is no clinical response or resistance to them is generated.

21 Oct 2021

Antidepressant Prozac could offer the first treatment for atrophic macular degeneration

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.

21 Oct 2021

Development of a plant-based platform for the production of SARS-CoV-2 antigen

Scientists have recently focused on the development of plant-based recombinant protein platforms.

21 Oct 2021

First-in-human study of DBS for post-stroke rehabilitation shows encouraging results

Targeting the dentate nucleus with deep brain stimulation (DBS) was safe and feasible for promoting post-stroke rehabilitation in a first-in-human study at Cleveland Clinic.

21 Oct 2021

Study paves the way for development of new therapeutic strategies to treat addiction

Drug addiction is a psychiatric disorder for which no pharmacological treatment with long-term efficacy currently exists. All addictive substances share the property of raising concentrations of the neurotransmitter dopamine within brain regions forming the neural reward circuit.

21 Oct 2021

Oxford vaccine trial participants believe the COVID-19 vaccine must be a shared global good

National pride in the Oxford-AstraZeneca vaccine does not outweigh desire for global greater good, suggests study with trial participants.

21 Oct 2021

Discovery could lead to new treatments for axial spondyloarthritis

In a paper published today in the journal Science Translational Medicine, researchers at the Schroeder Arthritis Institute, part of University Health Network in Toronto, have made a discovery that could lead to new treatments for axial spondyloarthritis (SpA), a painful and debilitating form of arthritis which affects 1-2% of Canadians and causes inflammation in the spine, joints, eyes, gut and skin.

20 Oct 2021

Using hydrogel barriers to effectively prevent post-surgical adhesions

Following surgery within the abdominal or pelvic cavities, scar tissue often forms on the inner linings of these cavities and may adhere to the organs which are found within them.

20 Oct 2021

New shorter treatment regimen found to be safer, more effective at treating drug-resistant TB

A new all-oral six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care, according to results announced at the 52nd Union World Conference on Lung Health.

20 Oct 2021

Study investigates whether continued magnetic seizure therapy can prevent relapse of depression

Treatment-resistant depression or TRD is exactly what it sounds like: a form of mental illness that defies effective therapy. It is not rare, with an estimated 3 million persons in the United States suffering from TRD.

20 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

Two doses of Pfizer-BioNTech vaccine effective in preventing COVID-19 hospitalization among adolescents

The Centres for Disease Control and Prevention conducted a study to determine the vaccination efficacy in the adolescent population, published recently.

20 Oct 2021

COVID-19 vaccination side effects in the USA

A new study described and compared self-reported side effects of three different COVID-19 vaccines administered between March 19 and July 15, 2021, in the United States.

20 Oct 2021

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.

20 Oct 2021

Efficacy News and Research

Honeybees can be trained to identify SARS-CoV-2 infected samples, say scientists

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

Comparative effectiveness of ChAdOx1 and BNT162b2 COVID-19 vaccines

Comparison of social distancing policies in Denmark and Sweden to combat COVID-19

U.S. life expectancy may drop for the second year, minorities most affected

Researchers identify a common gene variant that drives the efficiency and outcome of dialysis

CAR-T cell treatment's efficacy in hematological malignancies predicted by epigenetics

Antidepressant Prozac could offer the first treatment for atrophic macular degeneration

Development of a plant-based platform for the production of SARS-CoV-2 antigen

First-in-human study of DBS for post-stroke rehabilitation shows encouraging results

Study paves the way for development of new therapeutic strategies to treat addiction

Oxford vaccine trial participants believe the COVID-19 vaccine must be a shared global good

Discovery could lead to new treatments for axial spondyloarthritis

Using hydrogel barriers to effectively prevent post-surgical adhesions

New shorter treatment regimen found to be safer, more effective at treating drug-resistant TB

Study investigates whether continued magnetic seizure therapy can prevent relapse of depression

The neutralization potential of nanobodies against SARS-CoV-2

Two doses of Pfizer-BioNTech vaccine effective in preventing COVID-19 hospitalization among adolescents

COVID-19 vaccination side effects in the USA

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News